Previous 10 | Next 10 |
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference SAN DIEGO , Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b AD...
Arena Pharmaceuticals ([[ARNA]] +3.3%) has achieved its targeted enrollment goal of 372 participants in Phase 3 ELEVATE UC 52 trial evaluating etrasimod, for moderately-to-severely active ulcerative colitis. Though the company said that due to the high number of participants currently in queu...
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial SAN DIEGO , Dec. 8, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved its targeted enrollment goal of 372 participants in the...
Arena Pharmaceuticals, Inc. (ARNA) 3rd Annual Evercore ISI HealthCONx Conference December 01, 2020 04:20 PM ET Company Participants Amit Munshi - CEO Presentation Unidentified Analyst Thank you all for joining us. It's a pleasure to have the management and leadership team from Arena join us t...
Arena Pharmaceuticals to Present at the Evercore ISI HealthCONx Conference on December 1 PR Newswire SAN DIEGO, Nov. 24, 2020 SAN DIEGO , Nov. 24, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , th...
Gainers: [[XPER]] +27.4%. [[FLGT]] +16.7%. [[AHT]] +16.3%. [[GTHX]] +13.9%. [[SCOR]] +11.4%.Losers: [[SUPN]] -22.9%. [[BYND]] -22.4%. [[ARNA]] -17.8%. [[NEX]] -15.6%. [[YALA]] -13.4%. For further details see: XPER, SUPN, AHT and ARNA among after-hours movers
Shares of Arena Pharmaceuticals (NASDAQ: ARNA) are plummeting today, down by 22% as of 1:35 p.m. EST, after the biotech released data from a mid-stage study of etrasimod in patients with atopic dermatitis, commonly called eczema. The bad news is the study failed. The good news i...
Gainers: Greenland Technologies (GTEC) +170%.Revlon (REV) +86%.Summit Wireless Technologies (WISA) +50%.Trxade Group (MEDS) +29%.Inovio Pharmaceuticals (INO) +23%.Xperi Holding (XPER) +21%.Pulse Biosciences (PLSE) +21%.Aptevo Therapeutics (APVO) +21%.Boqii Holding (BQ) +20%.StarTek (SRT)...
Gainers: Trxade Group (MEDS) +35%, OPKO Health (OPK) +19%, Altimmune (ALT) +17%, Sientra (SIEN) +16%, Fulgent Genetics (FLGT) +8%.Losers: Arena Pharmaceuticals (ARNA) -25%, Voyager Therapeutics (VYGR) -21%, Aurora Cannabis (ACB) -21%, ...
Arena Pharmaceuticals, Inc. (ARNA) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Pat Malloy – Vice President, Investor Relations and Corporate Communications Amit Munshi – President and Chief Executive Officer Chris Cabell – Chief Medic...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...